A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer

Inclusion Criteria: * Histologically or cytologically confirmed extensive-stage small-cell lung cancer (SCLC). * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. * Adequate hematologic and organ function as confirmed by laboratory values Exclusion Criteria: * Clinically significant cardiac abnormalities including QRS duration of \>120 msec; QTcF \>470 msec for women and \>450 msec for men; Abnormal cardiac rhythm; Clinically significant cardiac valve abnormality; Documented history of left ventricular ejection fraction \<0.30 within 6 months; Permanent pacemaker or automatic implantable cardioverter defibrillator; History of torsades de pointes, congenital long QT syndrome, or family history of long QT syndrome or sudden death * Recent or ongoing serious infection * Women who are pregnant or breastfeeding * Prior exposure to a pyrrolobenzodiazepine (PBD)-based drug, prior participation in a rovalpituzumab tesirine clinical trial, or known hypersensitivity to rovalpituzumab tesirine or excipient contained in the drug formulation.